98%
921
2 minutes
20
Background: The diagnosis of monogenic obesity is burdened by frequent variants of uncertain significance (VUS). We describe our real-life approach of variant reassessment over time and we assess whether inconclusive variants are decreasing in monogenic obesity.
Methods: We tested for monogenic obesity (genes: LEPR, POMC, ADCY3, PCSK1, CARTPT, SIM1, MRAP2, LEP, NTRK2, BDNF, KSR2, MAGEL2, SH2B1, MC4R, MC3R) in 101 children/adolescents (11.7 [7.3-13.7] years, 3.6 [3.3-4.0] z-BMI) in Verona and 183 (11.3 [8.4-12.2] years, 3.2 [2.7-3.9] z-BMI) in Naples from January 2020 to February 2023. In March-July 2024 we reassessed the baseline variants by updated software interpretation and literature renavigation.
Results: We initially found 20 VUS, 4 Likely Pathogenic (LP), 5 Likely Benign (LB) and 1 benign variant in 33 individuals. At follow-up, 6 VUS were reclassified as benign/LB, one LP as pathogenic and 3 LB as benign. Overall, 10/30 variants (6/18 in Verona, 3/11 in Naples and a variant found in both centres) were reclassified, leading to a less uncertain report for 13 of 33 variant-carrying patients. Monogenic obesity was diagnosed in 3 probands in Verona and 4 in Naples, carrying variants at MC4R or NTRK2.
Conclusion: Our variant reassessment was effective to improve classification certainty for the 39% of patients and suggested that the molecular diagnosis of monogenic obesity is becoming more accurate over time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ijpo.13183 | DOI Listing |
J Clin Endocrinol Metab
September 2025
Department of Pediatrics II, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Background & Objective: The melanocortin-4 receptor agonist setmelanotide compensates for upstream gene defects in the brain leptin-melanocortin pathway and reduces hyperphagia and obesity in selected monogenic obesity forms and Bardet-Biedl syndrome (BBS). We aimed to evaluate the short-term impact of setmelanotide treatment in BBS presenting original real-world data focusing on metabolic dysfunction-associated steatotic liver disease (MASLD) and kidney function.
Methods: This monocentric, prospective observational cohort study was performed between June and December 2023 and included patients above the age of 6 years with genetically confirmed BBS, obesity and/or hyperphagia and planned setmelanotide therapy.
Obesity (Silver Spring)
September 2025
Assistance Publique Hôpitaux de Paris, Service de Nutrition, Centre Référent PRADORT "Syndrome de Prader-Willi et Autres Obésités Rares Avec Troubles du Comportement Alimentaire," Hôpital Pitié-Salpêtrière, Paris, France.
Objective: The melanocortin-4 receptor agonist setmelanotide has demonstrated effectiveness in phase 3 clinical trials for patients with monogenic obesity caused by biallelic variants in the leptin receptor (LEPR) and pro-opiomelanocortin (POMC), as well as for individuals with Bardet-Biedl syndrome (BBS). However, real-world evidence remains limited. This study evaluates the long-term effectiveness and safety of setmelanotide in patients who received treatment under a pre-marketing early-access authorization.
View Article and Find Full Text PDFDiabetes
September 2025
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
Dorzagliatin is a dual-acting allosteric glucokinase (GCK) activator that increases β-cell glucose sensitivity and second-phase insulin in GCK monogenic diabetes of the young. Actions of dorzagliatin on α- and β-cell function in normal and impaired glucose tolerance are unknown. In this study, dorzagliatin increased second-phase insulin in individuals with impaired glucose tolerance while suppressing glucagon in participants with normal glucose tolerance during a hyperglycemic clamp.
View Article and Find Full Text PDFBiophys J
August 2025
Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, PO Box 5400, 90014, Oulu, Finland.
Congenital leptin deficiency or dysfunction is a form of monogenic childhood obesity. The disease is primarily caused by mutations in the LEP gene, which encodes for the expression of a hormone called leptin. The mutations typically impair leptin synthesis, secretion, or binding to the leptin receptor (LepR).
View Article and Find Full Text PDFHipertens Riesgo Vasc
August 2025
Internal Medicine Department, University Hospital Virgen de las Nieves, Granada, Spain.
Hepatic steatosis is classified into several types according to its aetiology: metabolic; alcohol-related; metabolic with moderate alcohol consumption; associated with drugs or monogenic diseases, and cryptogenetic. An infrequent form of presentation is focal multinodular, and should be included in the differential diagnosis of solid liver lesions, which may simulate solid metastases. Magnetic resonance imaging is essential to identify the fat content and avoid unnecessary scans and invasive procedures such as biopsies.
View Article and Find Full Text PDF